Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops
Launched by SANTEN OY · Jan 16, 2008
Trial Information
Current as of May 23, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with a diagnosis of ocular hypertension or open angle glaucoma for which the patient has been using latanoprost 0.005% as his/her prior medication. - Evaluable patients must have ocular surface related symptoms and/or signs with their prior medication.
About Santen Oy
Santen Oy is a global pharmaceutical company specializing in the research, development, and commercialization of innovative therapies for ophthalmic conditions. With a strong commitment to improving patient outcomes, Santen focuses on addressing unmet medical needs in eye care through cutting-edge science and technology. The company leverages its extensive expertise in ophthalmology to drive clinical trials that evaluate the safety and efficacy of new treatments, enhancing the quality of life for individuals with vision-related disorders. As a trusted partner in the healthcare community, Santen Oy is dedicated to advancing eye health and fostering sustainable solutions for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tampere, , Finland
Patients applied
Trial Officials
Hannu Uusitalo, Professor
Principal Investigator
Finn-Medi Research, Finland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials